Home / Going-concern warnings / Serina Therapeutics, Inc.
Filed 2025-08-11 路 Form 10-Q 路 Accession 0001708599-25-000089 micro
Price before filing: $5.51 (2025-08-08 close, split/dividend-adjusted)
Market cap at flag: $52.7M (2025-08-11) 路 Latest: $28.2M (2026-10-16)
| Window | SER | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -8.9% | +2.4% | -11.3% | 2025-09-10 |
| 90 days | -27.6% | +7.2% | -34.8% | 2025-11-10 |
| 180 days | -59.2% | +9.5% | -68.7% | 2026-02-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 1 insider sold $236K (7 sales)
30 days after: 1 insider sold $383K (5 sales)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-06-30 | Moreadith Randall Chief Scientific Officer | Sale | 6,500 | $5.78 | $38K | yes | Form 4 |
| 2025-07-07 | Moreadith Randall Chief Scientific Officer | Sale | 6,500 | $5.67 | $37K | yes | Form 4 |
| 2025-07-14 | Moreadith Randall Chief Scientific Officer | Sale | 6,500 | $5.01 | $33K | no | Form 4 |
| 2025-07-21 | Moreadith Randall Chief Scientific Officer | Sale | 6,500 | $5.34 | $35K | no | Form 4 |
| 2025-07-28 | Moreadith Randall Chief Scientific Officer | Sale | 6,500 | $5.89 | $38K | no | Form 4 |
| 2025-07-29 | Moreadith Randall Chief Scientific Officer | Sale | 4,196 | $6.50 | $27K | yes | Form 4 |
| 2025-08-04 | Moreadith Randall Chief Scientific Officer | Sale | 5,500 | $5.17 | $28K | yes | Form 4 |
| 2025-08-11: red flag filed | |||||||
| 2025-08-12 | Moreadith Randall Chief Scientific Officer | Sale | 5,500 | $5.25 | $29K | yes | Form 4 |
| 2025-08-18 | Moreadith Randall Chief Scientific Officer | Sale | 2,227 | $5.25 | $12K | yes | Form 4 |
| 2025-08-20 | Moreadith Randall Chief Scientific Officer | Sale | 2,077 | $5.10 | $11K | yes | Form 4 |
| 2025-08-25 | Moreadith Randall Chief Scientific Officer | Sale | 2,042 | $5.65 | $12K | yes | Form 4 |
| 2025-08-26 | Moreadith Randall Chief Scientific Officer | Sale | 45,632 | $7.01 | $320K | yes | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-05-13 to 2025-09-10. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As such, there is substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.